EVOGENE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 238.4 ILa | +1.02% |
|
+1.88% | -20.48% |
| 05-23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
| 05-23 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.48% | 32.08M | - | - | |
| +38.65% | 39.36B | A | ||
| -8.62% | 38.52B | B | ||
| +26.95% | 30.74B | B | ||
| +10.74% | 25.92B | B- | ||
| -13.50% | 26.03B | C | ||
| +44.87% | 14.13B | B+ | ||
| +34.36% | 12.73B | C+ | ||
| -7.14% | 11.29B | B+ | ||
| -12.61% | 10.64B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EVGN Stock
- Ratings Evogene Ltd.
